Skip to main content

Table 4 Annual reinfection rate of Helicobacter pylori

From: Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy

 

Follow up period

No. of patients

Mean no. of H. pylori test

No. of reinfected patients

Patient-years (yr)

Annual reinfection rate (%)

 

1 ≤ year <2

23

1.39

3

33.08

9.07

E

2 ≤ year <3

18

2.22

3

42.25

7.10

B

3 ≤ year <4

5

2.00

0

16.58

0

M

4 ≤ year <5

8

2.63

0

34.67

0

T

5 ≤ year <6

3

6.00

1

16.58

6.03

 

6 ≤ year <7

1

5.00

0

6.5

0

7 ≤ year <8

1

5.00

0

7.5

0

Total

59

2.05

7

157.17

4.45

 

1 ≤ year <2

39

1.36

8

54.12

14.78

M

2 ≤ year <3

37

2.05

8

91.75

8.72

E

3 ≤ year <4

30

3.67

1

104.58

0.96

A

4 ≤ year <5

10

3.80

2

43.33

4.62

 

Total

116

2.31

19

294.08

6.46

  1. EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.).